Moclobemide, a relatively new antidepressant whose pharmacological actions are mediated via a reversible inhibition of monoamine oxidase subtype A! (RIMA), and fluoxetine, a selective serotonin uptake inhibitor 2 (SSRI) are antidepressant drugs which are achieving increasing clinical use because of their efficacy and lower incidence of side-effects compared to the tricyclic antidepressants. Despite their relative safety when taken singly in overdose 3 -\ when taken in overdose together or in combination with other antidepressants, significant toxicity may be seen 5 ,7 ,S. The case history of a patient who presented following overdose of moclobemide, clomipramine and fluoxetine is outlined. The patient developed a classical serotonin syndrome with severe hyperthermia and died from the subsequent complications of fulminant disseminated intravascular coagulation (DIC) and multiple organ failure.
CASE REPORT
A 40-year-old, 40 kg female, presented to hospital approximately two hours after ingesting an overdose of the following tablets: moclobemide 150 mg x 40, clomipramine 25 mg x 12, fluoxetine 20 mg x 17, and clonazepam 1 mg x 12.
Admission examination revealed the patient to be drowsy but readily rousable with no focal neurological signs. Temperature was normal, pulse rate 80 beats per minute and blood pressure 110/80 mmHg. There were no other clinical abnormalities. The electrocardiogram showed sinus rhythm, QRS duration of 100 mseconds and QTc interval of 0.40 seconds. Investigations revealed blood alcohol of 0.145 g/dl and a "total" tricyclic antidepressant level of 722 p.g clomipramine/l (estimated by the TDx polycIonal assay technique; Abbott Diagnostics, Australia).
Initial management included gastric lavage and administration of 50g nasogastric charcoal. She was admitted to a medical ward and neurological observations overnight showed a Glasgow Coma Scale Score (GCS) of 13 on admission decreasing to 8 some four hours later. Eight hours after admission the patient was noted to be shaking and restless with hyperextension of her legs and spine. At 10 hours post admission she was unrousable with a GCS of 3, decerebrate posturing, hyperventilation and hyperpyrexia (43°C). Her skin was dry and pupils were large and non-reactive. Urgent resuscitation was commenced and continued en route to the Intensive Care Unit (ICU).
Intubation was performed and controlled ventilation with pharmacological paralysis initiated. Active cooling was commenced with ice-packs to the groin and axillae, and gastric lavage with ice-cold solutions. Her temperature was returned to 37°C within 90 min of admission to ICV. The pulse rate was 110 per minute and BP 110/55 mmHg. A central venous catheter was inserted. Central venous pressure initially measured o mmHg, rising to 9 mmHg over the next four hours with the infusion of 4.5 litres of colloid and thereafter was maintained at or above this level. A urinary catheter was inserted and drained 1,850 ml urine over the first hour followed by 100 ml over the next hour with no urine in the following two hours. After continued resuscitation 20g IV mannitol was given. Urine output over the next 24 hours was generally more than 100 ml per hour.
Serial blood samples were taken during her time in ICU ( Progressive deterioration occurred in the 24 hours prior to death. Abdominal distension and colonic bleeding developed requiring transfusion. Blood gas analyses showed increasing metabolic acidosis. Creatine kinase levels were markedly elevated with a peak of 26,700 U/l and progressive oliguria was unresponsive to standard support. Respiratory failure with radiological changes of bilateral pulmonary infiltrates (CVP 12 mmHg) required treatment with PEEP (10 cm H 2 0) and high concentrations of oxygen (Fi0 2 =1). Hypotension was unresponsive to treatment with adrenaline (0.5 j.tg/kg/min), noradrenaline (0.25 j.tg/kg/min) and dobutamine (15 j.tg/kg/min). Death occurred 60 hours following admission as a result of refractory hypotension, mutiple organ failure and coagulopathy.
Autopsy was performed. As well as the extensive skin bruising and petechial changes, there were scattered petechiae throughout the myocardium, bowel and adrenals. There was pulmonary oedema. The brain was sectioned and was normal.
Serial measurement of the plasma concentration of moclobemide, its three major metabolites, as well as clomipramine, desmethylclomipramine, fluoxetine, and norfluoxetine were made by specific high performance liquid chromatographic methods··IO. This data is summarized in Figure 1 . Levels of moclobemide declined initially with a half-life of around 5h, while clomipramine and its active metabolite des methylclomipramine both declined with a half-life of 22h in the first 3Ih after admission. Plasma concentrations of fluoxetine ranged from 38-90 j.tg/l and norfluoxetine from 12-58 j.tg/l during this time. Clearances of moclobemide, clomipramine, fluoxetine and their respective metabolites were significantly compromised starting some 3Ih after admission. Benzodiazepines were detected in the initial blood sample, but not quantified. The serotinin syndrome is considered to be present when coincident with an increase in dose, or the addition of a known serotonergic agent to a patient's medication, they develop at least three of the following symptoms; mental state changes (confusion, hypomania), agitation, myoclonus, hyperreflexia, diaphoresis, shivering, tremor, diarrhoea, incoordination and fever. The syndrome can result in intracranial bleeding, coma, cardiovascular collapse, respiratory distress and a fatal hyperthermia 11-13. Sternbach (1991) reviewed the drug interactions causing the serotonin syndrome in a combined series of 38 patients!!. MAOIs implicated in causation were generally "classical" agents such as phenelzine and tranylcypromine. L-tryptophan, fluoxetine and clomipramine were the most commonly implicated serotonergic agents. Recent reports record the serotonin syndrome following combined use of newer reversible monoamine oxidase A inhibitors (RIMA) and serotonergic agents, particularly in overdose. Moclobemide, a RIMA, causes minimal toxicity following overdose alone 3 -6 . Ingestion of up to 20g of moclobemide has been documented without major toxicity. There is evidence for a more severe intoxication following overdose of moclobemide and tricyclic antidepressants s • A series of seven overdose cases involving moclobemide (O.75-7.5g) in combination with other central nervous depressants reported symptoms such as convulsions, coma, muscle rigidity and hyperthermia. Recent reports document the serotonin syndrome when serotonergic agents such as citalopram or clomipramine 7 or imipramine 8 are used with moclobemide. In common with symptoms seen in our patient, these reports describe a clinical picture of hyperthermia, with or without extensor spasms and raised creatine kinase levels. Eventually five out of six patients in these studies died.
Plasma concentration measurements confirmed a combined overdose of moclobemide and clomipramine. Initial plasma concentrations of moclobemide and its three major metabolites were threefold lower than those previously reported for overdose cases involving moclobemide alone 6 but were nevertheless seven to nine times steady-state concentrations seen after therapeutic doses!'. Plasma concentration of clomipramine plus desmethylclomipramine was about twice the value for the upper end of the usual therapeutic range lS . These levels were consistent with overdose, but not sufficiently high to anticipate marked toxic effects from the drug per se. Plasma concentrations of fluoxetine and norfluoxetine were at the lower end of the usual concentration range found after therapeutic doses of fluoxetine!6.
Our patient developed classical features of the serotonin syndrome. Clinicians were misled by reports of the safety of the agents taken in overdose alone and by the absence of initial toxic features. Muscular rigidity and hyperthermia only developed after a latent period. Hyperthermia was a significant feature and despite rapid and successful initiation of body cooling, the subsequent course of rhabdomyolysis, DIC and multiple organ failure was consistent with that seen after severe hyperpyrexia. Clinically it was felt that the overdose precipitated the hyperpyrexia and that this was the cause of death rather than ongoing direct drug toxicity. A similar clinical syndrome with fatal hyperthermia has been reported following methylenedioxymethylamphetamine (MD MA, "Ecstasy") or methylenedioxyethylamphetamine (MD EA, "Eve") ab use 17,!8.
The hyperpyrexia of the serotonin syndrome is thought to be triggered centrally via elevated 5-HT and increased muscular activityll,13. Surface cooling and cooled intravenous fluids may be sufficient to control pyrexia in mild cases, while muscle paralysis and barbiturates may be useful in more severe cases!3. Earlier treatment of rigidity in our patient may have lessened hyperpyrexia. Animal studies note that pretreatment with p-chlorophenylalanine, methysergide and cyproheptadine may prevent the syndrome!l but no clear clinical guidelines for their role in human treatment are available. Chlorpromazine!9 has been suggested to be beneficial in treatment of both hyperpyrexia and rigidity, but caution is needed where there is hypotension and the syndrome has still developed in patients receiving chlorpromazine 2o . While dantrolene has been used to combat the hyperpyrexia 20 , its use remains controversial". We believe the threshold for intubation and paralysis in patients unresponsive to the above treatments should be low.
No abnormal pressor response to adrenaline was seen in our patient but the absence of pulmonary artery catheter (not inserted because of coagulopathy) precludes descriptions of the effect of therapy on cardiac output and vascular resistance. Certainly in patients having taken MAOIs, all sympathomimetic agents should be titrated cautiously. Indirect acting agents such as ephedrine may have more potential for an exaggerated response. Non-reactive mid-sized pupils have been described in MAOI overdose! and are probably due to sympathetic activation. No structural lesion was found on brain computerized tomography nor at autopsy in our patient.
The role of the SSRI fluoxetine in this case is worthy of consideration. Its antidepressant action is due to its inhibition of neuronal uptake of 5-HT in the CNS 2 . Although plasma levels of fluoxetine and norfluoxetine were low in the present case, these agents may well have contributed to the observed hyperserotonergic syndrome via inhibition of 5-HT uptake.
The serotonin syndrome has also been described when clomipramine has been taken at therapeutic doses with MAOIs or in close temporal relationship to them. Spigset 22 has reported a case of serotonin syndrome in a patient who started moclobemide (300 mg/day) one day after ceasing clomipramine (50 mg/day). Severe symptoms appeared within one day and the patient recovered fully after five days. The psychiatric literature documents an increasing trend to combine moclobemide and SSRIs in the treatment of resistant depression. Whilst early studies suggest this to be safe if closely monitored with tight dose controFJ·24, clinicians need to be vigilant for development of the syndrome in this group. Toxicity in our patient appears to have arisen as a result of an interaction of clomipramine and moclobemide. Clinicians should be aware that fulminating serotonergic syndrome may develop in patients presenting with combined overdoses of newer RIMAs and serotonergic drugs despite seemingly apparent safety of the agents when taken alone in overdose. The syndrome may develop after a latent period. Patients should be appropriately monitored with complications being anticipated and treated according to standard MAOI overdose guidelines.
